Swedbank Has $40.92 Million Holdings in Allergan plc (AGN)

Swedbank reduced its stake in shares of Allergan plc (NYSE:AGN) by 66.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 245,463 shares of the company’s stock after selling 492,534 shares during the quarter. Swedbank owned about 0.07% of Allergan worth $40,924,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Avestar Capital LLC bought a new stake in Allergan during the fourth quarter worth approximately $113,000. Captrust Financial Advisors bought a new stake in Allergan during the fourth quarter worth approximately $175,000. Bfsg LLC bought a new stake in Allergan during the first quarter worth approximately $206,000. Wayne Hummer Investments L.L.C. bought a new stake in Allergan during the first quarter worth approximately $211,000. Finally, RMB Capital Management LLC bought a new stake in Allergan during the first quarter worth approximately $213,000. 79.28% of the stock is currently owned by institutional investors.

Get Allergan alerts:

Shares of Allergan opened at $176.84 on Tuesday, according to MarketBeat.com. The company has a quick ratio of 0.94, a current ratio of 1.10 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $59.20 billion, a P/E ratio of 10.41, a PEG ratio of 1.25 and a beta of 1.13. Allergan plc has a 52-week low of $142.81 and a 52-week high of $256.80.

Allergan (NYSE:AGN) last announced its quarterly earnings results on Monday, April 30th. The company reported $3.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.36 by $0.38. The firm had revenue of $3.67 billion during the quarter, compared to analyst estimates of $3.59 billion. Allergan had a positive return on equity of 8.53% and a negative net margin of 11.94%. Allergan’s quarterly revenue was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.35 earnings per share. analysts anticipate that Allergan plc will post 16.06 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, June 15th. Shareholders of record on Friday, May 18th were issued a dividend of $0.72 per share. The ex-dividend date of this dividend was Thursday, May 17th. This represents a $2.88 dividend on an annualized basis and a yield of 1.63%. Allergan’s dividend payout ratio is currently 17.61%.

Several equities research analysts have weighed in on the company. Piper Jaffray Companies set a $161.00 price objective on Allergan and gave the stock a “hold” rating in a research note on Thursday, May 31st. JPMorgan Chase & Co. set a $265.00 price objective on Allergan and gave the stock a “buy” rating in a research note on Thursday, March 15th. Cantor Fitzgerald set a $191.00 target price on Allergan and gave the company a “hold” rating in a research note on Friday, April 27th. Mizuho reaffirmed a “neutral” rating and set a $194.00 target price on shares of Allergan in a research note on Monday. Finally, Vetr cut Allergan from a “strong-buy” rating to a “buy” rating and set a $183.43 target price on the stock. in a research note on Thursday, March 15th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and sixteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $209.15.

In other Allergan news, EVP William Meury sold 24,425 shares of the company’s stock in a transaction on Thursday, May 17th. The stock was sold at an average price of $154.59, for a total transaction of $3,775,860.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.37% of the stock is owned by corporate insiders.

Allergan Company Profile

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).